Author: dev_team

England & Company is pleased to announce that it has served as the exclusive financial advisor to YData Labs, Inc. (“YData” or the “Company”) on its pending acquisition by KPMG US. This transaction deepens England’s Technology footprint advising companies across the Artificial Intelligence (“AI”) and broader IT infrastructure ecosystem.

YData was founded in 2019 to unlock the power of synthetic data to accelerate innovation, ensure privacy, and enable AI through improved quality data. What started as a vision to make data more accessible grew into a platform trusted by teams around the world.

With this acquisition, KPMG will strengthen its AI client offerings, harness synthetic data to enhance AI-enabled client delivery for Audit and Assurance, Tax and Advisory services, and establish a Synthetic Data Center of Excellence designed to accelerate innovation and safeguard client confidentiality.

Gonçalo Martins Ribeiro, Founder and CEO of YData, commented, “England was an exceptional partner throughout this process. Their deep understanding of the AI infrastructure ecosystem and connectivity into key stakeholders coupled with expert process guidance, was instrumental in allowing YData to position the Company to play a key role in how synthetic data will shape the future of AI.”

“In a rapidly evolving AI landscape, synthetic data is playing a key role in testing, training and deploying solutions while balancing privacy, compliance and time-to-value demands,” noted England Managing Director, Joel Strauch. “YData combines a leading-edge platform with deep technical expertise to build, test, and scale synthetic data to support AI. We’re honored to have had the opportunity to partner with the YData team and look forward to seeing their continued success as part of KPMG.”

England & Company is pleased to announce that NIRx Medical Technologies, LLC (“NIRx”), a pioneer in functional Near-Infrared Spectroscopy (fNIRS) neuroimaging systems and the market leader in this rapidly growing market, has been acquired by Gilde Healthcare Partners BV (“Gilde”), a Netherlands-based healthcare investor specializing medtech, digital health, and therapeutics. NIRx’s systems enable non-invasive, radiation-free, real-time brain imaging for neuroscience research in both lab and natural settings. As part of a strategic combination, Gilde has also acquired Artinis Medical Systems B.V. (“Artinis”), a complementary fNIRS company. This combination creates a global leader in fNIRS and is the foundation for building a market leader in innovative neuroimaging and neuroscience research tools more broadly.

NIRx Group CEO, Richard Barbour, said: “The England team added significant value in negotiating this transaction and bringing it to a successful close. They also went above and beyond with additional financial advisory assistance.” Dr. Patrick Britz, CEO of NIRx GmbH added “It was really a pleasure working with the England team. Their support, attention to detail, diligence, and advice on the deal were instrumental in achieving this amazing result.”

NIRx provides cutting-edge solutions to researchers in human neuroscience to enhance the understanding of the human mind, health, and disease. Through its innovative and comfortable-wearing head gear, NIRx offers a host of integrated technology solutions that support a wide range of investigative aims – from exploring early language acquisition in infants to motor movements in the natural environment to BCI applications or new understandings involving coordinated actions between sensory systems, NIRS imaging solutions from NIRx constitute a comprehensive resource that meet the most demanding applications.

As established leaders in fNIRS, NIRx and Artinis will merge as a newly formed platform within Gilde for neuroimaging and corresponding research tools, all while driving innovation across multiple modalities. The goal of this new platform is to enhance the adoption of fNIRS in applied neuroscience by setting industry standards and making the technology more accessible to academic and institutional researchers globally.

“By bringing both companies together, we are creating a platform that will lead innovation and makes brain imaging tools more accessible to researchers globally,” said Boyd Rutten, Investment Director, Gilde Healthcare.

June 2022 – England Securities served as acquisition & restructuring advisor to Ara Partners (“Ara”), in its acquisition of Genera, Inc (“Genera”).

Ara is a private equity firm specializing in industrial decarbonization investments. Ara invests in the industrial & manufacturing, chemicals & materials, energy efficiency & green fuels, and food & agriculture sectors, seeking to build businesses that are focused on sustainability and ESG principles.

“Genera was a complicated transaction that required the England & Company team, working closely with Ara Partners and other advisors, to create a mutually beneficial acquisition and restructuring,” said Troy Thacker, Managing Partner of Ara. “It’s a tremendous benefit to work with a trusted, capable partner on complicated situations that require out-of-the-box creative structuring.”

Genera’s facility, once fully operational, will process agricultural crops such as switchgrass into ag-based fiber and the Earthable® line of sustainable food-grade, compostable packaging. The facility, which is the largest fully integrated domestic solution for ag-based fiber and food packaging in North America, will host 160 employees at full production.